Sun Pharma gets DCGI nod to launch generic Semaglutide injection for weight loss in India
Company to launch product after the expiry of semaglutide patent in India
Company to launch product after the expiry of semaglutide patent in India
Developed using STEERLife’s proprietary FragMelt continuous processing platform, the approval marks a major breakthrough in pharmaceutical manufacturing
Dr. Reddy’s Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7% is an antihistamine eye drop, indicated for the temporary relief of itchy eyes due to pollen, ragweed, grass, animal hair and dander
This product has only one approved generic and one authorized generic with an addressable market share of US$ 172 million
Tablets will be manufactured at Granules' US-based facility located in Chantilly, Virginia
The approval comes with 180 days of Competitive Generic Therapy (CGT) exclusivity,
Conjugated Estrogens Tablets are indicated for moderate to severe menopausal symptoms, including hot flashes, and for the prevention of postmenopausal osteoporosis in women at significant risk
With US$ 30.46 billion in exports and robust manufacturing capabilities, the industry is poised to expand into high-value drugs while strengthening ESG and compliance standards
The product is indicated for the chronic management of patients with Urea Cycle Disorders
Subscribe To Our Newsletter & Stay Updated